2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
"2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A selective D1 dopamine receptor agonist used primarily as a research tool.
| Descriptor ID |
D015647
|
| MeSH Number(s) |
D03.633.100.079.800
|
| Concept/Terms |
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine- 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
- 1H-3-Benzazepine-7,8-diol, 2,3,4,5-tetrahydro-1-phenyl-
SK&F-38393- SK&F-38393
- SK&F 38393
- SK&F38393
- SKF38393
- SKF-38393
- SKF 38393
- R-SK&F 38393
- RSK&F 38393
- SKF 38393-A
- SKF 38393 A
- SKF 38393A
|
Below are MeSH descriptors whose meaning is more general than "2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine".
Below are MeSH descriptors whose meaning is more specific than "2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine".
This graph shows the total number of publications written about "2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine" by people in this website by year, and whether "2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1998 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine" by people in Profiles.
-
Giri R, Alberts I, Harding WW. Synthesis, pharmacological evaluations, and molecular docking studies on a new 1,3,4,11b-tetrahydro-1H-fluoreno[9,1-cd]azepine framework: Rigidification of D1 receptor selective 1-phenylbenzazepines and discovery of a new 5-HT6 receptor scaffold. Chem Biol Drug Des. 2020 08; 96(2):825-835.
-
Lee KN, Pellom ST, Oliver E, Chirwa S. Characterization of the guinea pig animal model and subsequent comparison of the behavioral effects of selective dopaminergic drugs and methamphetamine. Synapse. 2014 May; 68(5):221-33.
-
Williams S, Mmbaga N, Chirwa S. Dopaminergic D1 receptor agonist SKF 38393 induces GAP-43 expression and long-term potentiation in hippocampus in vivo. Neurosci Lett. 2006 Jul 10; 402(1-2):46-50.
-
Sakamoto K, Liu C, Kasamatsu M, Pozdeyev NV, Iuvone PM, Tosini G. Dopamine regulates melanopsin mRNA expression in intrinsically photosensitive retinal ganglion cells. Eur J Neurosci. 2005 Dec; 22(12):3129-36.
-
Mazzio E, Becker A, Soliman KF. Characterization of neurotransmitters and dopamine attenuation of inducible nitric oxide synthase in glioma cells. J Neuroimmunol. 2002 Oct; 131(1-2):70-82.
-
Durham RA, Johnson JD, Eaton MJ, Moore KE, Lookingland KJ. Opposing roles for dopamine D1 and D2 receptors in the regulation of hypothalamic tuberoinfundibular dopamine neurons. Eur J Pharmacol. 1998 Aug 21; 355(2-3):141-7.
-
Johnson DE, Ochieng J, Evans SL. The growth inhibitory properties of a dopamine agonist (SKF 38393) on MCF-7 cells. Anticancer Drugs. 1995 Jun; 6(3):471-4.